Evidence-Based Medicine
Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis
Abstract
Background: Lung cancer remains the leading cause of cancer-related deaths in men and the second leading cause in women worldwide. It is becoming increasingly clear that estrogen and estrogen receptors are involved in the pathogenesis and development of lung cancer. However, observational studies on the prognostic role of estrogen receptor β (ERβ) in non-small cell lung cancer (NSCLC) are controversial.
Methods: To clarify the impact of ERβ in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival.
Results: A total of eleven studies with 3,300 patients were evaluable for this meta-analysis. Our results suggested that ERβ overexpression had no relationship on survival of patients with NSCLC, the HR (95% CI) was 1.000 (0.954–1.047) overall. Moreover, there was no heterogeneity between the studies.
Conclusions: ERβ overexpression indicates no relationship of prognosis for patients with NSCLC.
Methods: To clarify the impact of ERβ in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival.
Results: A total of eleven studies with 3,300 patients were evaluable for this meta-analysis. Our results suggested that ERβ overexpression had no relationship on survival of patients with NSCLC, the HR (95% CI) was 1.000 (0.954–1.047) overall. Moreover, there was no heterogeneity between the studies.
Conclusions: ERβ overexpression indicates no relationship of prognosis for patients with NSCLC.
